Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Century Therapeutics to $12 from $9 and keeps an Overweight rating on the shares. The firm notes Century is preparing to initiate the Phase I CALiPSO-1 study of CD-19 iNK CNTY-101 in SLE with initial data in Q4 2024, and expects to expand into additional autoimmune diseases. At ASCO, Phase I ELiPSE-1 data showed CNTY-101 achieved ORR of 40%, including 3 CRs and 1 PR in B cell lymphoma patients. Importantly, no cases of GvHD or DLTs were reported.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics presents interim results from Phase 1 ELiPSE-1 study
- Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
- Century Therapeutics files to sell 15.87M shares of common stock for holders
- Century announces two presentations on CNTY-101 at ASGCT 27th Annual Meeting
- Century Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com